Kerry David Fisher

List of Publications by Year
in descending order

73 papers	3,026 citations	185998 28 h-index	182168 51 g-index
73 all docs	73 docs citations	73 times ranked	3463 citing authors

#	Article	IF	Citations
1	Tackling HLA Deficiencies Head on with Oncolytic Viruses. Cancers, 2021, 13, 719.	1.7	6
2	Polymer stealthing and mucin-1 retargeting for enhanced pharmacokinetics of an oncolytic vaccinia virus. Molecular Therapy - Oncolytics, 2021, 21, 47-61.	2.0	8
3	Deregulation of HLA-I in cancer and its central importance for immunotherapy. , 2021, 9, e002899.		73
4	The role of cancer metabolism in defining the success of oncolytic viro-immunotherapy. Cytokine and Growth Factor Reviews, 2020, 56, 115-123.	3.2	5
5	A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR). Radiation Oncology, 2020, 15, 151.	1.2	14
6	NK Cells Augment Oncolytic Adenovirus Cytotoxicity in Ovarian Cancer. Molecular Therapy - Oncolytics, 2020, 16, 289-301.	2.0	29
7	External Beam Radiation Therapy and Enadenotucirev: Inhibition of the DDR and Mechanisms of Radiation-Mediated Virus Increase. Cancers, 2020, 12, 798.	1.7	11
8	A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE). , 2019, 7, 20.		68
9	Polyvalent Diazonium Polymers Provide Efficient Protection of Oncolytic Adenovirus Enadenotucirev from Neutralizing Antibodies while Maintaining Biological Activity <i>In Vitro</i> and <i>In Vivo</i>. Bioconjugate Chemistry, 2019, 30, 1244-1257.	1.8	17
10	Bi- and tri-valent T cell engagers deplete tumour-associated macrophages in cancer patient samples. , 2019, 7, 320.		58
11	Solid Tumor Immunotherapy with T Cell Engagerâ€Armed Oncolytic Viruses. Macromolecular Bioscience, 2018, 18, 1700187.	2.1	56
12	An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells. Cancer Research, 2018, 78, 6852-6865.	0.4	123
13	Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirusÂin murine cancer cells. , 2018, 6, 55.		16
14	Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators. Molecular Therapy - Oncolytics, 2017, 4, 18-30.	2.0	37
15	OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution. Molecular Therapy - Oncolytics, 2017, 4, 55-66.	2.0	17
16	Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer. Virology, 2017, 505, 162-171.	1.1	16
17	Oncolytic adenovirus expressing bispecific antibody targets Tâ€cell cytotoxicity in cancer biopsies. EMBO Molecular Medicine, 2017, 9, 1067-1087.	3.3	104
18	Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus. Molecular Therapy - Oncolytics, 2017, 5, 62-74.	2.0	40

#	Article	IF	Citations
19	Making Oncolytic Virotherapy a Clinical Reality: The European Contribution. Human Gene Therapy, 2017, 28, 1033-1046.	1.4	14
20	Combining Oncolytic Adenovirus with Radiationâ€"A Paradigm for the Future of Radiosensitization. Frontiers in Oncology, 2017, 7, 153.	1.3	32
21	Development of a versatile oncolytic virus platform for local intra-tumoural expression of therapeutic transgenes. PLoS ONE, 2017, 12, e0177810.	1.1	23
22	Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection. , 2017, 5, 71.		113
23	Oncolytic viruses: finally delivering. British Journal of Cancer, 2016, 114, 357-361.	2.9	95
24	A PTENtial cause for the selectivity of oncolytic viruses?. Nature Immunology, 2016, 17, 225-226.	7.0	8
25	Under Pressure: Elevated Blood Pressure Enhances Targeting of Tumors by Oncolytic Viruses. Molecular Therapy, 2016, 24, 204-205.	3.7	4
26	Actin-resistant DNAse I Expression From Oncolytic Adenovirus Enadenotucirev Enhances Its Intratumoral Spread and Reduces Tumor Growth. Molecular Therapy, 2016, 24, 796-804.	3.7	29
27	A phase I/II study of enadenotucirev, a chimeric Ad11/Ad3 oncolytic group B adenovirus, administered intraperitoneally (IP) in platinum-resistant epithelial ovarian cancer: Pharmacokinetic (PK) and tolerability data from phase I.. Journal of Clinical Oncology, 2016, 34, 5543-5543.	0.8	2
28	Improved <i>In Vitro</i> Human Tumor Models for Cancer Gene Therapy. Human Gene Therapy, 2015, 26, 249-256.	1.4	6
29	Macrophages and their interactions with oncolytic viruses. Current Opinion in Pharmacology, 2015, 24, 23-29.	1.7	10
30	In vivo characterization of the physicochemical properties of polymer-linked TLR agonists that enhance vaccine immunogenicity. Nature Biotechnology, 2015, 33, 1201-1210.	9.4	362
31	Abstract 295: Delivery of checkpoint inhibitor antibodies and other therapeutics directly to tumors by encoding them within the oncolytic adenovirus enadenotucirev. , 2015, , .		0
32	Inertial cavitation to non-invasively trigger and monitor intratumoral release of drug from intravenously delivered liposomes. Journal of Controlled Release, 2014, 178, 101-107.	4.8	73
33	"Arming" the chimeric oncolytic adenovirus enadenotucirev to deliver checkpoint inhibitors and other therapeutics directly to tumours. , 2014, 2, .		1
34	Development of a Positive-readout Mouse Model of siRNA Pharmacodynamics. Molecular Therapy - Nucleic Acids, 2013, 2, e133.	2.3	8
35	Tropism ablation and stealthing of oncolytic adenovirus enhances systemic delivery to tumors and improves virotherapy of cancer. Nanomedicine, 2012, 7, 1683-1695.	1.7	23
36	Recombinant viral vaccines for cancer. Trends in Molecular Medicine, 2012, 18, 564-574.	3.5	35

#	Article	IF	Citations
37	Virotherapy â€“ cancer targeted pharmacology. Drug Discovery Today, 2012, 17, 215-220.	3.2	13
38	Targeting adenovirus gene delivery to activated tumour-associated vasculature via endothelial selectins. Journal of Controlled Release, 2011, 150, 196-203.	4.8	29
39	Tumour necrosis factor-alpha increases extravasation of virus particles into tumour tissue by activating the Rho A/Rho kinase pathway. Journal of Controlled Release, 2011, 156, 381-389.	4.8	49
40	E-selectin is a viable route of infection for polymer-coated adenovirus retargeting in TNF-Î±-activated human umbilical vein endothelial cells. Journal of Drug Targeting, 2011, 19, 690-700.	2.1	10
41	Adenovirus: Teaching an Old Dog New Tricks. Human Gene Therapy, 2011, 22, 1041-1042.	1.4	6
42	HPMA copolymers for masking and retargeting of therapeutic virusesâ˜†. Advanced Drug Delivery Reviews, 2010, 62, 240-245.	6.6	78
43	Adenovirus-Derived Vectors for Prostate Cancer Gene Therapy. Human Gene Therapy, 2010, 21, 795-805.	1.4	29
44	Preclinical Screening of Gene Therapy in Human Tissues. Human Gene Therapy, 2009, 20, 291-292.	1.4	5
45	Cetuximab Retargeting of Adenovirus via the Epidermal Growth Factor Receptor for Treatment of Intraperitoneal Ovarian Cancer. Human Gene Therapy, 2009, 20, 239-251.	1.4	37
46	Quantification of siRNA using competitive qPCR. Nucleic Acids Research, 2009, 37, e4-e4.	6.5	19
47	Coating of adenovirus type 5 with polymers containing quaternary amines prevents binding to blood components. Journal of Controlled Release, 2009, 135, 152-158.	4.8	52
48	Pâ€selectin dependent targeting to inflamed endothelium of recombinant Pâ€selectin glycoprotein ligandâ€1 immunoglobulin chimeraâ€coated poly[<i>N</i>â€(2â€hydroxypropyl) methacrylamide]â€DNA polyplexes <i>in vivo</i> visualised by intravital microscopy. Journal of Gene Medicine, 2009, 11, 326-334.	1.4	7
49	<i>In vitro</i> evaluation of a â€˜stealthâ€™ adenoviral vector for targeted gene delivery to adult mammalian neurones. Journal of Gene Medicine, 2009, 11, 335-344.	1.4	7
50	Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood, 2009, 113, 1909-1918.	0.6	183
51	Establishment of a positive-readout reporter system for siRNAs. Journal of Rnai and Gene Silencing, 2009, 5, 331-8.	1.2	4
52	Retargeting polymerâ€coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer. Journal of Gene Medicine, 2008, 10, 280-289.	1.4	52
53	Coating of adenoâ€associated virus with reactive polymers can ablate virus tropism, enable retargeting and provide resistance to neutralising antisera. Journal of Gene Medicine, 2008, 10, 400-411.	1.4	55
54	Cancer gene therapy with targeted adenoviruses. Expert Opinion on Drug Delivery, 2008, 5, 1231-1240.	2.4	43

#	Article	IF	Citations
55	Virotherapy of Ovarian Cancer With Polymer-cloaked Adenovirus Retargeted to the Epidermal Growth Factor Receptor. Molecular Therapy, 2008, 16, 244-251.	3.7	81
56	Directed Evolution Generates a Novel Oncolytic Virus for the Treatment of Colon Cancer. PLoS ONE, 2008, 3, e2409.	1.1	158
57	Cetuximab retargeting of adenovirus via the epidermal growth factor receptor for treatment of intraperitoneal ovarian cancer. Human Gene Therapy, 2008, .	1.4	1
58	Comparison of Molecular Strategies for Breast Cancer Virotherapy using Oncolytic Adenovirus. Human Gene Therapy, 2008, .	1.4	0
59	DYNAMICS OF POLYDISPERSE IRREVERSIBLE ADSORPTION: A PHARMACOLOGICAL EXAMPLE. Mathematical Models and Methods in Applied Sciences, 2007, 17, 759-781.	1.7	9
60	Passive tumour targeting of polymer-coated adenovirus for cancer gene therapy. Journal of Drug Targeting, 2007, 15, 546-551.	2.1	45
61	Bacteriophage biopanning in human tumour biopsies to identify cancer-specific targeting ligands. Journal of Drug Targeting, 2007, 15, 311-319.	2.1	6
62	Adenovirus Type 5 Interactions with Human Blood Cells May Compromise Systemic Delivery. Molecular Therapy, 2006, 14, 118-128.	3.7	138
63	Striking out at disseminated metastases: the systemic delivery of oncolytic viruses. Current Opinion in Molecular Therapeutics, 2006, 8, 301-13.	2.8	47
64	Glycoviruses: Chemical Glycosylation Retargets Adenoviral Gene Transfer. Angewandte Chemie - International Edition, 2005, 44, 1057-1061.	7.2	41
65	Cover Picture: Glycoviruses: Chemical Glycosylation Retargets Adenoviral Gene Transfer (Angew.) Tj ETQq1 1 0.784314 rgBT /Overlock 1	7.2	0
66	Glycoviruses: Chemical Glycosylation Retargets Adenoviral Gene Transfer. Angewandte Chemie, 2005, 117, 1081-1085.	1.6	1
67	Titelbild: Glycoviruses: Chemical Glycosylation Retargets Adenoviral Gene Transfer (Angew. Chem.) Tj ETQq1 1 0.784314 rgBT /Overlock	1.6	0
68	Enhanced gene transfer activity of peptide-targeted gene-delivery vectors. Journal of Drug Targeting, 2005, 13, 39-51.	2.1	37
69	Use of a Phage Display Library to Identify Oligopeptides Binding to the Lumenal Surface of Polarized Endothelium byEx VivoPerfusion of Human Umbilical Veins. Journal of Drug Targeting, 2003, 11, 53-59.	2.1	25
70	Identification of FGF receptor-binding peptides for cancer gene therapy. Cancer Gene Therapy, 2002, 9, 543-552.	2.2	58
71	Decreased Binding to Proteins and Cells of Polymeric Gene Delivery Vectors Surface Modified with a Multivalent Hydrophilic Polymer and Retargeting through Attachment of Transferrin. Journal of Biological Chemistry, 2000, 275, 3793-3802.	1.6	148
72	Turbidometric analysis of polyelectrolyte complexes formed between poly(l-lysine) and DNA. Colloids and Surfaces B: Biointerfaces, 1999, 16, 253-260.	2.5	13

#	Article	IF	Citations
73	A Sensitive Assay System for the Determination of Poly(L-Lysine) Concentration Using Turbidometry. Journal of Bioactive and Compatible Polymers, 1999, 14, 122-136.	0.8	4